ARTICLES|ONLINE FIRST Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial Mahir Karakas, Ibrahim Akin, Christoph Burdelski, et al Lancet Respir Med Published: December 08, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00439-2 Summary Background Cardiogenic shock has a high mortality on optimal therapy. Adrenomedullin is released ...

ARTICLES| VOLUME 9, ISSUE 12, P1427-1438, DECEMBER 01, 2021 Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial Jozefien Declercq, Karel F A Van Damme, Elisabeth De Leeuw, et al Lancet Respir Med 2021; 9: 1427-1438 Summary Background Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interleukin (IL)-1 and IL-6 ...

ARTICLES| VOLUME 9, ISSUE 12, P1419-1426, DECEMBER 01, 2021 Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet Respir Med 2021; 9: 1419-1426 Summary Background Colchicine has been proposed as a treatment for COVID-19 based on its anti-inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients admitte...

Original Investigation December 21, 2021 Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, et al JAMA. 2021;326(23):2375-2384. doi:10.1001/jama.2021.21316 Abstract Importance  Proactive therapeutic drug monitoring (TDM...

ARTICLES|ONLINE FIRST Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial Eduardo Ramacciotti, Leandro Barile Agati, Daniela Calderaro, et al Lancet Published:December 15, 2021 DOI:https://doi.org/10.1016/S0140-6736(21)02392-8 Summary Background Patients hospitalised with COVID-19 are at risk for thrombotic events after disch...

ARTICLES| VOLUME 399, ISSUE 10321, P237-248, JANUARY 15, 2022 Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial Scott A Halperin, Lingyun Ye, Donna MacKinnon-Cameron, et al Lancet 2022; 399: 237-248 Summary Background ...

Original Investigation December 20, 2021 Effect of Regional vs General Anesthesia on Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery: The RAGA Randomized Trial Ting Li, Jun Li, Liyong Yuan, et al JAMA. Published online December 20, 2021. doi:10.1001/jama.2021.22647 Abstract Importance  In adults undergoing hip fracture surgery, regional anesthesia may reduce postoperative delirium, but there is ...

ARTICLES|ONLINE FIRST Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial Arabella S V Stuart, Robert H Shaw, Xinxue Liu, et al Lancet Published:December 06, 2021 DOI:https://doi.org/10.1016/S0140-6736(21)02718-5 Summary Background Given the importance of flexible use of di...

ARTICLES| VOLUME 398, ISSUE 10318, P2258-2276, DECEMBER 18, 2021 Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial Alasdair P S Munro, Leila Janani, Victoria Cornelius, et al Lancet 2021; 398: 2258-2276 Summary Background Few data exist on the comparative safety and immunogenicity of differen...

Original Investigation December 13, 2021 Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial Peter A. Dargaville, C. Omar F. Kamlin, Francesca Orsini, et al JAMA. Published online December 13, 2021. doi:10.1001/jama.2021.21892 Abstract Importance  The benefits of surfactant administrati...